Kura Oncology, Inc. (KURA) Discusses Updated FIT 001 Trial Results for Darlifarnib and Cabozantinib in Renal Cell Carcinoma Transcript
We bridge the gap between financial information and actionable insight by providing unrivaled coverage on all asset classes and access to best-in-class tools. My name is Stephen, and I will be your conference operator today. At this time, I'd like to welcome you to the Kura Oncology Investor Call to discuss updated results from the FIT-001 clinical trial evaluating darlifarnib in combination with cabozantinib in renal cell carcinoma. [Operator Instructions].
- ▪We bridge the gap between financial information and actionable insight by providing unrivaled coverage on all asset classes and access to best-in-class tools.
- ▪My name is Stephen, and I will be your conference operator today.
- ▪At this time, I'd like to welcome you to the Kura Oncology Investor Call to discuss updated results from the FIT-001 clinical trial evaluating darlifarnib in combination with cabozantinib in renal cell carcinoma. [Operator Instructions].
Seeking Alpha files mainly under finance. We currently carry 6,778 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | Seeking Alpha |
| Canonical URL | https://seekingalpha.com/article/4925879-kura-oncology-inc-kura-discusses-updated-fit-001-trial-results-for-darlifarnib-and?source=feed_all_articles |
| Publication time | Mon, 27 Jul 2026 15:38:52 -0400 |
| Retrieval time | 2026-07-27T19:53:58.939Z |
| Last seen | 2026-07-27T19:53:58.939Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | 22UTrSVkoQ1j · 1 stories |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4925879-kura-oncology-inc-kura-discusses-updated-fit-001-trial-results-for-darlifarnib-and"},"author":{"@type":"Person","name":"SA Transcripts","url":"https://seekingalpha.com/author/sa-transcripts"},"publisher":{"@context":"https://schema.org","@type":"Organization","address":{"@type":"PostalAddress","streetAddress":"244 5th Ave","addressLocality":"New York","addressRegion":"NY","postalCode":"10001","addressCountry":"US"},"alternateName":["SeekingAlpha","SA"],"brand":[{"@type":"Brand","name":"Seeking Alpha Premium","url":"https://seekingalpha.com/subscriptions/premium"},{"@type":"Brand","name":"Seeking Alpha…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
